Functional Parameters of ¹⁸F-FDG PET/CT in Patients with Primary Testicular Diffuse Large B-Cell Lymphoma

Table 1

Baseline characteristics of the patients.

No	Age	Ann Arbor stage	IPI score	ECOG performance status	Site	Nodal involvement	Exnodal involvement	Ki-67	β2 microglobulin (mg/L)	LDH (IU/L)	Treatment
1	37	IVB	3	0	Bilateral	Para-aortic lymph node	Bilateral kidney, perirenal region, and spleen	80%	2.33	237	Orchiectomy, CT, and prophylactic intrathecal injection
2	73	IVB	3	0	Right	Abdominal lymph node	Lung and nasopharyngeal wall	40%	2.63	177	Orchiectomy, CT, RT, and prophylactic intrathecal injection
3	57	IVB	3	1	Left	Neck lymph node	Maxillary sinus, maxillary bone, orbital cavity, temporalis, multiple subcutaneous tissue, and bone of trunk	60%	2.82	301	Orchiectomy and CT
4	58	IEA	1	0	Left	—	—	N/A	N/A	223	Orchiectomy, CT, and RT
5	73	IVA	3	0	Bilateral	Cervical lymph nodes and hilar lymph node	Skin	50%	2.19	246	Orchiectomy, CT, and prophylactic intrathecal injection
6	58	IVB	3	0	Left	Multiple lymph nodes	Kidney, adrenal gland, and spermatic cord	90%	NA	367	Orchiectomy and CT + prophylactic intrathecal injection

IPI, International Prognostic Index; NCCN IPI, National Comprehensive Cancer Network International Prognostic Index; ECOG performance status, Eastern Cooperative Oncology Group performance status; LDH, lactic dehydrogenase; CT, chemotherapy; RT, radiotherapy; N/A, not applicable.